PMBS Stock | News | Quote | Stock Forum | Thursday, January 9,

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
$PMBS PuraMed BioScience, Inc. PMBS Company Overview 

PuraMed BioScience, Inc. PMBS Current Price and Quotes
Last Price 0.0015
Previous Close 0.0021 Open 0.0022
Daily Range 0.0024 - 0.0015 52wk Range 0.015 - 0.0012
Volume 25,935,341 Dividend N/A
Average Vol (3m) 4,883,360 Yield N/A

PMBS Stock Message Board http://investorshangout.com/search?q=PMBS&...mp;yt1=Go!

Last Updated: Thursday, January 9, 2014 01:19:00 AM

PuraMed BioScience, Inc. PMBS
Company Information

1326 Schofield Avenue
Schofield, WI 54476

Phone: 715-359-6373

PuraMed BioScience, Inc. PMBS
PuraMed BioScience, Inc. PMBS
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Sep 30, 2013 10-Q
CIK 0001409565
Fiscal Year End 6/30
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Dec 31, 2007
Incorporated In: MN, USA
Year of Inc. 2006
Employees Not Available
Company Officers/Contacts

Russell W. Mitchell CEO, Interim CFO
James W. Higgins COO
Company Directors

Russell W. Mitchell Chairman
Service Providers

Auditor/Accountant
Tanner LLC
215 South State St.
Suite 800
Salt Lake City, UT, 84111
United States

Legal Counsel
Lucosky Brookman LLP
33 Wood Avenue South
Woodbridge, NJ, 08830
United States

Investor Relations Firm
Not Available

PuraMed BioScience, Inc. PMBS
PMBS Security Details

Share Structure

Market Value1 $272,757 a/o Jan 08, 2014
Shares Outstanding 129,884,289 a/o Dec 31, 2013
Float Not Available
Authorized Shares 1,000,000,000 a/o Sep 30, 2013
Par Value  0.001
Shareholders

Shareholders of Record 317 a/o Oct 15, 2013
Short Selling Data

Short Interest 0 (-100%)
Dec 13, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

Interwest Transfer Co., Inc.

PuraMed BioScience, Inc. PMBS Financials
Period Ending Jun 30, 2013 Jun 30, 2012 Jun 30, 2011 Jun 30, 2010
Total Revenue 43 693 9 32
Cost of Revenue 95 184 7 14
Gross Profit (53) 509 1 18
Operating Expenses

Research and Development 75 18 59 109
Sales, General and Admin. 1,823 1,789 981 1,162
Non-Recurring Items - - - -
Other 55 51 49 49
Operating Income (2,006) (1,349) (1,087) (1,302)
Income From Continuing Operations

Add'l Income/Expense Items (28) 103 (77) -
Earnings Before Interest and Tax (2,034) (1,246) (1,164) (1,301)
Interest Expense 529 476 325 180
Earnings Before Tax (2,563) (1,721) (1,489) (1,481)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (2,657) (1,721) (1,489) (1,481)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (2,563) (1,721) (1,489) (1,481)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (2,563) (1,721) (1,489) (1,481)

PuraMed BioScience, Inc. PMBS Recent News

Nov 29, 2013 LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations


PMBS PuraMed BioScience, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=PMBS&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PMBS/quote
Stock Chart http://www.otcmarkets.com/stock/PMBS/chart
Company Info http://www.otcmarkets.com/stock/PMBS/company-info
Recent News http://www.otcmarkets.com/stock/PMBS/news
Financials http://www.otcmarkets.com/stock/PMBS/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PMBS/filings
Short Sales http://www.otcmarkets.com/stock/PMBS/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PMBS/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PMBS/research
Summary http://finance.yahoo.com/q?s=PMBS
Historical Prices http://finance.yahoo.com/q/hp?s=PMBS+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PMBS
Basic Chart http://finance.yahoo.com/q/bc?s=PMBS+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PMBS+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PMBS+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PMBS+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PMBS+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PMBS+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PMBS+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PMBS+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PMBS+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PMBS+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PMBS
Balance Sheet http://finance.yahoo.com/q/bs?s=PMBS
Cash Flow http://finance.yahoo.com/q/cf?s=PMBS+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PMBS
Market Watch http://www.marketwatch.com/investing/stock/PMBS
Bloomberg http://www.bloomberg.com/quote/PMBS:US
Morningstar http://quotes.morningstar.com/stock/s?t=PMBS
Bussinessweek http://investing.businessweek.com/research/st...icker=PMBS
Barchart http://www.barchart.com/quotes/stocks/PMBS
OTC Short Report http://otcshortreport.com/index.php?index=PMBS
Investopedia http://www.investopedia.com/markets/stocks/PMBS/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading